Clinical Trials Logo

Neoplasm, Plasma Cell clinical trials

View clinical trials related to Neoplasm, Plasma Cell.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05573802 Recruiting - Multiple Myeloma Clinical Trials

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Start date: July 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2, open-label study designed to assess the safety and clinical activity of different belantamab mafodotin doses in combination with lenalidomide, dexamethasone and nirogacestat in patients with transplant ineligible newly diagnosed multiple myeloma. This will be a 2-part study. In part 1 participants will be enrolled in one cohort to receive belantamab mafodotin in combination with lenalidomide, dexamethasone and nirogacestat and will determine the recommended phase 2 dose (RP2D) to be further evaluated for safety and clinical activity in the dose expansion cohort. The RP2D dose will be used in future studies in the transplant-ineligible newly diagnosed multiple myeloma (NDMM) setting. In the dose expansion phase (Part 2) an expansion cohort will be treated with the RP2D. The expansion cohort will randomize participants (1:1) in two groups to evaluate two alternate dose modification guidelines for corneal AEs. Part 2 of the study will also evaluate an alternative dose modification guideline for corneal adverse events (AEs). Overall, approximately 36 participants will be enrolled in the study. Participant follow-up will continue up to 3 years after the last participant is enrolled (follow-up period range: 3-4 years). The estimated accrual period will be 12 months, corresponding to an approximate total study duration of 4 years.

NCT ID: NCT05101759 Recruiting - Lymphoma Clinical Trials

Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological Malignancy

LYMPHOLD
Start date: October 1, 2022
Phase: N/A
Study type: Interventional

The aim of the study is to assess the prevalence of functional decline in elderly patients treated with chemotherapy or immunochemotherapy for lymphoid hematologic malignancies. For this purpose, each patient benefits at inclusion (D0) of a standardized gerontological evaluation, and 3 and 6 months post-inclusion.

NCT ID: NCT04776330 Recruiting - Multiple Myeloma Clinical Trials

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Start date: March 7, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

NCT ID: NCT04272151 Recruiting - Multiple Myeloma Clinical Trials

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Start date: December 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

NCT ID: NCT04271644 Recruiting - Multiple Myeloma Clinical Trials

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Start date: April 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.